Halozyme Therapeutics, Inc.
HALO
$48.58
-$1.65-3.29%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 35.22% | 29.55% | 34.28% | 4.67% | 20.81% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 35.22% | 29.55% | 34.28% | 4.67% | 20.81% |
| Cost of Revenue | 63.01% | -15.13% | -5.90% | -13.11% | -40.41% |
| Gross Profit | 29.86% | 50.58% | 54.42% | 12.87% | 50.66% |
| SG&A Expenses | 20.57% | 12.34% | 16.93% | -8.31% | -5.95% |
| Depreciation & Amortization | -0.01% | 0.00% | -0.44% | -0.41% | -0.40% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.91% | -5.04% | 1.30% | -9.85% | -7.39% |
| Operating Income | 48.14% | 73.70% | 79.77% | 24.11% | 77.58% |
| Income Before Tax | 49.78% | 76.14% | 62.29% | 26.39% | 83.83% |
| Income Tax Expenses | 33.99% | 160.99% | 41.22% | 33.13% | 52.14% |
| Earnings from Continuing Operations | 53.72% | 60.46% | 67.42% | 24.74% | 93.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 53.72% | 60.46% | 67.42% | 24.74% | 93.92% |
| EBIT | 48.14% | 73.70% | 79.77% | 24.11% | 77.58% |
| EBITDA | 40.35% | 61.52% | 65.66% | 19.69% | 56.94% |
| EPS Basic | 58.36% | 63.83% | 74.18% | 29.25% | 106.27% |
| Normalized Basic EPS | 56.34% | 81.90% | 88.66% | 30.97% | 94.15% |
| EPS Diluted | 55.00% | 62.31% | 72.13% | 28.57% | 106.90% |
| Normalized Diluted EPS | 54.43% | 81.01% | 86.86% | 30.62% | 95.27% |
| Average Basic Shares Outstanding | -2.94% | -2.05% | -3.88% | -3.50% | -5.99% |
| Average Diluted Shares Outstanding | -1.74% | -1.57% | -2.95% | -3.24% | -6.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |